Camlin Fine Sciences Reports INR 250 Crore Rights Issue Plan

Camlin Fine Sciences plans to raise INR 250 crore via a rights issue to boost working capital and liquidity. Management targets a Q4 top-line recovery to INR 600 crore with EBITDA exceeding INR 60 crore.

Reader Takeaway: The rights issue provides necessary liquidity to manage operations, though profitability remains pressured by high input costs.

What just happened

Camlin Fine Sciences Ltd has announced a Board-approved rights issue of INR 250 crore. The capital infusion is primarily aimed at augmenting working capital to alleviate severe liquidity stress that has forced the company to rely on expensive channel financing. Promoters have committed to supporting the issue to ensure its successful closure, which is expected by the end of the calendar year.

Why this matters

The company is navigating a difficult period characterized by constrained growth and compressed margins. Consolidated EBITDA margins fell to 2.5% from 3.4% as raw material volatility and financing costs increased. The rights issue is viewed as a critical lever to stabilize the balance sheet, as the current liquidity crunch has hindered the company's ability to maintain optimal production levels.

The backstory

Recent performance has been uneven across segments. The Aroma business saw revenue drop to INR 472 million from INR 774 million due to capacity utilization issues. Meanwhile, the Diphenol plant remains closed since May 2026, rendered unviable by intense competition from Chinese producers and high input costs. The company is now shifting its sales strategy to distributors to reduce reliance on credit-heavy transactions with large users.

What changes now

Management has explicitly characterized the current performance as not encouraging and expects Q3 to remain challenging. However, the outlook for Q4 FY27 assumes that the successful capital raise will normalize working capital, allowing the business to hit internal targets of INR 600 crore revenue and INR 60 crore EBITDA.

Risks to watch

The primary risk remains execution. The Q4 recovery target is heavily conditional on the swift completion of the rights issue. Furthermore, pricing power in the Aroma segment remains weak, and the company continues to face challenges in passing on raw material cost increases to customers.

What to track next

Investors should monitor the draft offer document filing, expected by November 4, 2026, and the progress of the rights issue subscription. Ongoing operational metrics from the specialty ingredients segment, which showed margin improvement to 8.04%, will also be key to assessing the underlying health of the core business.